Vir Biotechnology VIR
NASDAQ VIR
$10.77 +0.03 (+0.28%)
As of: Oct 21, 2026 · 10:15 AM EDT

Vir Biotechnology (VIR) Receivables - Other (2021)

Updated

Vir Biotechnology's Receivables - Other was $112.5 million in Q1 2021.

Analysis

Vir Biotechnology (VIR) Receivables - Other (2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,130.97 Bn 1,099.55 Bn 19.71 Bn
2 Johnson & Johnson 614.97 Bn 533.50 Bn 17.26 Bn
3 AbbVie 505.56 Bn 478.67 Bn 12.70 Bn
4 Merck 366.86 Bn 321.23 Bn 12.21 Bn
5 Novartis Ag 297.80 Bn 261.79 Bn 11.24 Bn
6 Astrazeneca 261.62 Bn 235.31 Bn 12.86 Bn
7 Amgen 235.78 Bn 191.18 Bn 7.24 Bn
8 Gilead Sciences 189.91 Bn 164.11 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Vir Biotechnology 1.81 Bn -144.76 Mn 238.95 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 112.50 Mn
API Access

Vir Biotechnology Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=VIR&period=max&api_key=YOUR_API_KEY